Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.8 ILa | -1.18% | -1.18% | -56.02% |
Sales 2024 * | 14.36M 5.42B | Sales 2025 * | 27.77M 10.48B | Capitalization | 54.17M 20.44B |
---|---|---|---|---|---|
Net income 2024 * | -47M -17.74B | Net income 2025 * | -36M -13.59B | EV / Sales 2024 * | 3.77 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-
| Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
1 day | -1.18% | ||
1 week | -1.75% | ||
Current month | -40.21% | ||
1 month | -49.40% | ||
3 months | -51.45% | ||
6 months | -53.72% | ||
Current year | -56.02% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 62 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 16.8 | -1.18% | 491 903 |
24-04-21 | 17 | +1.80% | 678,535 |
24-04-18 | 16.7 | -2.34% | 1,098,013 |
24-04-17 | 17.1 | +0.59% | 2,295,728 |
24-04-16 | 17 | -5.56% | 2,308,134 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 24, 2024 at 07:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.02% | 53.92M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.11% | 22.19B | |
-16.16% | 21.33B | |
-7.10% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- BLRX Stock